Patents by Inventor Ian Schoenhofen

Ian Schoenhofen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • therapeutic based on CMP-nonulosonate sugars
    Patent number: 10865222
    Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: December 15, 2020
    Assignees: National Research Council of Canada, University of Massachusetts Medical School
    Inventors: Ian Schoenhofen, Dennis M. Whitfield, Sanjay Ram
  • Novel Neisseria Gonorrhoeae Therapeutic Based on CMP-Nonulosonate Sugars
    Publication number: 20170362269
    Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
    Type: Application
    Filed: September 1, 2017
    Publication date: December 21, 2017
    Applicants: National Research Council of Canada, University of Massachusetts Medical School
    Inventors: Ian SCHOENHOFEN, Dennis M. WHITFIELD, Sanjay RAM
  • therapeutic based on CMP-nonulosonate sugars
    Patent number: 9765106
    Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogs to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 19, 2017
    Assignee: National Research Council of Canada
    Inventors: Ian Schoenhofen, Dennis M. Whitfield, Sanjay Ram
  • Novel Neisseria gonorrhoeae therapeutic based on CMP-nonulosonate sugars
    Publication number: 20150232502
    Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
    Type: Application
    Filed: February 20, 2015
    Publication date: August 20, 2015
    Applicants: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL, NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Ian Schoenhofen, Dennis M. Whitfield, Sanjay RAM
  • Enzymatic degradation of lipid A fatty acids of bacterial LPS
    Patent number: 8975043
    Abstract: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mold Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: March 10, 2015
    Assignee: National Research Council of Canada
    Inventors: Andrew Cox, Dhamodharan Neelamegan, Ian Schoenhofen, Frank St. Michael, James Richards
  • Bacterial Antigens and Uses Thereof
    Publication number: 20080317775
    Abstract: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
    Type: Application
    Filed: November 23, 2006
    Publication date: December 25, 2008
    Inventors: Andrew Cox, Dhamodharan Neelamegan, Ian Schoenhofen, Frank St. Michael, James Richards